What Is NAD+ and Why Is It Important? (NAD+ vs NADH)

Every cell you have runs on a molecule it cannot store, cannot import intact, and has to rebuild on a clock measured in hours. That molecule spends its whole working life flipping between two forms, and that flip is exactly where most explanations fall apart.

We supply NAD+ as a research compound, and the technical questions labs send us are almost never about benefits. They're about the redox pair. So that's where anyone searching 'what is NAD+ and why is it important' should start too.

What is NAD+ and why is it important?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell that shuttles electrons between metabolic reactions and acts as a consumable substrate for repair enzymes. It matters because no cell makes ATP without continuously cycling NAD+ into NADH and back, a turnover research suggests happens within hours.

The common oversimplification is that NAD+ is a form of energy. It isn't. It's a carrier and a substrate, and NADH isn't a competing molecule but the same molecule holding cargo. This piece covers the components of NAD+, the direction of the redox reaction, whether vitamin B3 raises NAD+ levels, and what the published research does and doesn't demonstrate.

The components of NAD+, piece by piece

NAD+ is a dinucleotide, meaning two nucleotides joined tail to tail through a pair of bridging phosphate groups. One half is adenosine monophosphate (AMP), carrying the same adenine base and ribose sugar found in ATP and DNA. The other half is nicotinamide mononucleotide (NMN), built from the vitamin B3 derivative nicotinamide attached to its own ribose and phosphate.

So the full parts list is short: one adenine, one nicotinamide, two ribose sugars, two phosphates. Molecular weight lands around 663 g/mol for the free acid, which is large for something that has to move through cellular compartments constantly.

The nicotinamide ring does the actual chemistry. Its C4 position accepts a hydride ion, and the positive charge sits on the ring nitrogen, which is where the plus sign comes from. The plus does not mean more, better, or upgraded. It's a charge notation, nothing else.

One close relative deserves a mention because it gets conflated constantly. NAD kinase phosphorylates the 2-hydroxyl on the adenosine ribose to make NADP+, and the NADPH pool that results serves reductive biosynthesis and antioxidant recycling, including the glutathione reductase reaction that regenerates reduced glutathione. Same backbone, separate pool, different job.

The plus sign is a frequent source of confusion about the molecule.

NAD+ vs NADH: which form is which, and which one matters

NAD+ is reduced to NADH, not the reverse. If you've read that NADH is reduced to NAD+, that's the reaction described backwards: NADH is oxidized back to NAD+ when it hands its electrons off.

Dehydrogenase enzymes strip a hydride, one proton plus two electrons, from a substrate and load it onto NAD+. Glyceraldehyde-3-phosphate dehydrogenase does this in glycolysis. Isocitrate dehydrogenase and malate dehydrogenase do it in the TCA cycle. Beta-oxidation of fatty acids does it too. NADH then carries that cargo to Complex I of the electron transport chain (NADH:ubiquinone oxidoreductase), where the electrons flow downhill, protons get pumped, and ATP synthase does the rest. Standard P/O estimates put the yield at roughly 2.5 ATP per NADH.

The regeneration step is the one people skip. Without NAD+ coming back, glycolysis stalls at the GAPDH step almost immediately, which is precisely why lactate dehydrogenase exists: converting pyruvate to lactate regenerates NAD+ when oxygen is scarce.

Is NADH the same as NAD+? Same molecular scaffold, two oxidation states, opposite roles. Which is better, NAD+ or NADH? That's a category error. What the literature actually tracks is the ratio, and it's compartmentalised: classic metabolite-indicator estimates put the free cytosolic NAD+/NADH ratio in the hundreds to one, while the mitochondrial matrix pool sits dramatically lower. We see that distinction missed in half the assay questions we get.

Where NAD+ goes: consumption, precursors, and whether B3 raises it

Beyond redox cycling, NAD+ is destroyed and rebuilt constantly because an entire enzyme family consumes it as a substrate rather than recycling it. Sirtuins (SIRT1 through SIRT7, NAD+-dependent deacylases), PARPs (poly(ADP-ribose) polymerases, which respond to DNA damage), and CD38 (a cell-surface NADase) all cleave the glycosidic bond between nicotinamide and ribose, releasing free nicotinamide.

That's why the salvage pathway is the dominant route. NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme converting nicotinamide back to NMN, and the NMNAT enzymes adenylylate NMN into finished NAD+.

Does B3 increase NAD+? Yes, in the sense that every B3 vitamer feeds a biosynthetic route: nicotinic acid enters through the Preiss-Handler pathway via NAPRT, nicotinamide enters through salvage via NAMPT, and nicotinamide riboside is phosphorylated by NRK1 and NRK2. Tryptophan supports de novo synthesis through the kynurenine pathway, inefficiently. Human work published in Nature Communications by Trammell and colleagues in 2016 reported that oral nicotinamide riboside is bioavailable and raises blood NAD+, and a 2018 Nature Communications trial by Martens and colleagues reported elevated NAD+ in peripheral blood mononuclear cells with chronic NR intake.

Here's the part most summaries omit. Intact NAD+ is a large, negatively charged dinucleotide and doesn't simply cross the plasma membrane. Research indicates ectoenzymes including CD38 and CD73 dismantle extracellular NAD+ into nicotinamide riboside and nicotinamide before transport, meaning cells take delivery as precursors regardless of what the starting material was. Everything described here is laboratory biochemistry; research-grade NAD+ is not an FDA-approved drug and isn't for human or veterinary consumption.

Quick comparison: the NAD family and its precursors

The table below separates the two oxidation states, the phosphorylated cousin, and the three B3 vitamers that feed the pool. It exists because these seven items get treated as interchangeable in most consumer-facing writing, and they aren't.

What If: common NAD+ research scenarios

What if a source says NADH is reduced to NAD+?

Treat that source as unreliable on redox chemistry generally. The reduction runs NAD+ to NADH, and the reverse direction is an oxidation. This reversal appears often enough in consumer health writing that it's a fast credibility filter, and it usually travels alongside the claim that NADH is a separate, superior compound.

What if a product claims it delivers NAD+ directly into cells?

Read that claim against the membrane transport literature before accepting it. The intact dinucleotide is large and charged, and ectoenzymes including CD38 and CD73 cleave extracellular NAD+ into nicotinamide riboside and nicotinamide before transporters move anything inward. A claim of direct intracellular delivery of intact NAD+ needs specific supporting data, not a mechanism diagram.

What if B3 from a normal diet already covers NAD+ synthesis?

Dietary B3 does supply the substrate, which is why frank deficiency (pellagra) is rare where food is fortified. The open research question isn't substrate availability at baseline, it's whether pushing precursor intake above adequacy meaningfully shifts tissue NAD+ and, separately, whether that shift changes any functional endpoint. Those are two different questions and the evidence quality differs sharply between them.

What if the research model involves live animals?

Route the work through an approved institutional animal care protocol first, and talk to your veterinarian before anything else. Rodent NAD+ literature is extensive, but species differences in NAMPT expression, CD38 activity and precursor handling mean mouse pharmacokinetics don't transfer cleanly to other species. A licensed veterinarian is the right party to review any in vivo plan. A supplier is not.

The unglamorous truth about NAD+ supplement research

Here's the honest answer: raising a biomarker and changing an outcome are not the same achievement, and the NAD+ field has done far more of the first than the second. Published human trials have repeatedly shown that oral precursors elevate measurable NAD+ in blood compartments, often within days. What remains thin is the functional endpoint data, because most trials have been small, short, and focused on safety and pharmacokinetics rather than hard outcomes. Anyone asking whether NAD+ supplements are worth it should know that the measurement moves reliably and the clinical picture is still being assembled.

Our NAD+ materials and their documentation sit in a few places on our site: the NAD+ research overview covers the biochemistry background, while NAD+ 100mg and the NAD+ liquid spray list specifications for laboratory work, every batch has third-party documentation on the certificates of analysis page, and the rest of the research compounds are catalogued in the full shop. All materials are sold strictly for laboratory research use and are not for human or veterinary consumption.

Strip away the marketing and 'what is NAD+ and why is it important' reduces to a cycle rather than a substance. The molecule isn't valuable because it's present, it's valuable because it keeps moving, accepting a hydride here and releasing it there thousands of times before an enzyme finally consumes it and the salvage pathway builds another. Anything that treats NAD+ as a quantity to be topped up, rather than a flux to be sustained, has already lost the biochemistry. That distinction is where the interesting research still lives.

What is the difference between NAD+ and NADP+?

NAD+ and NADP+ are the same core molecule with one structural difference: NADP+ carries an additional phosphate group on the 2' hydroxyl of the adenosine ribose. That single phosphate changes which enzymes recognise the cofactor, and it splits the cell's redox economy into two largely separate pools. NAD+ and its reduced partner serve catabolic reactions, accepting electrons from glycolysis, fatty acid oxidation and the TCA cycle. NADP+ and NADPH serve anabolic and antioxidant chemistry, supplying reducing equivalents for fatty acid and cholesterol synthesis and for regenerating reduced thioredoxin and glutathione, a theme covered further in the notes on glutathione components. The enzyme NAD kinase makes NADP+ from NAD+ using ATP, so the two pools are linked but not interchangeable in practice.

For laboratory purposes this matters because assay kits, standards and chromatographic methods are pool-specific; an NAD+ cycling assay will not report NADP+ accurately without separate reagents. Reference material for either nucleotide should arrive with a certificate of analysis showing HPLC purity and mass confirmation, stored lyophilised, cold and protected from light and moisture. Investigators comparing redox cofactors alongside other research compounds often group both within broader longevity-focused research panels.

What is the difference between NAD+ and NADH?

NAD+ and NADH are the oxidised and reduced states of a single dinucleotide, not two different molecules. NAD+ has an electron-deficient, positively charged nicotinamide ring that acts as an electron acceptor. When it picks up a hydride, the ring becomes the uncharged, electron-rich NADH, which then acts as an electron donor to complex I of the mitochondrial electron transport chain or to cytosolic reductases. The interconversion is continuous; cells turn the pool over many times per day rather than consuming it.

Practically, the two forms behave differently in the laboratory. NADH absorbs strongly at 340 nm while NAD+ does not, which is why so many enzyme assays are read as a change in absorbance at that wavelength. NADH is also less stable in acid, whereas NAD+ degrades faster in alkaline conditions, so extraction chemistry must be chosen to match the species being measured. Lyophilised standards of both should be stored cold and dry, with HPLC and mass spectrometry data on the certificate of analysis confirming identity, a verification habit discussed in the guidance on assessing supplier legitimacy. Redox balance is a recurring variable in metabolic research compounds and in work with methyltransferase-targeting materials such as 5-amino-1MQ.

Is NAD+ to NADH oxidation or reduction, and how many electrons are transferred?

Going from NAD+ to NADH is a reduction. NAD+ is the oxidising agent in the reaction; it accepts electrons and is therefore reduced, while the substrate that gave up those electrons is oxidised. The transfer happens as a hydride ion, written H minus, which is one proton accompanied by two electrons. So two electrons move to the nicotinamide ring at carbon 4, and a separate free proton is released into solution. This is why the balanced form of dehydrogenase reactions is usually written as NAD+ plus two hydrogens yielding NADH plus H+.

The reverse direction, NADH back to NAD+, is an oxidation and returns those two electrons to an acceptor such as complex I or lactate dehydrogenase. Because the hydride lands on a specific ring face, dehydrogenases are stereospecific, a detail exploited in isotope labelling studies. Teams measuring this chemistry rely on 340 nm absorbance or on enzymatic cycling, and they confirm standard identity with HPLC and mass spectrometry before trusting kinetics. Redox stoichiometry also governs antioxidant recycling, which overlaps with the chemistry described for glutathione ingredients. General handling principles for research-grade materials and buffer incompatibilities outlined in what not to mix apply to cofactor stocks as well.

What does NAD+ stand for?

NAD+ stands for nicotinamide adenine dinucleotide. The name is literal: the molecule is a dinucleotide, meaning two nucleotides joined through their phosphate groups. One nucleotide carries nicotinamide as its base, the other carries adenine. Each base sits on a ribose sugar, and the two riboses are bridged by a pyrophosphate linkage. The superscript plus sign is not a charge on the whole molecule; it denotes the positively charged quaternary nitrogen in the oxidised nicotinamide ring. Writing simply NAD generally refers to the cofactor without specifying redox state, while NAD+ and NADH specify oxidised and reduced forms.

Older literature from the 1930s and 1940s used names like coenzyme I, diphosphopyridine nucleotide and DPN, all describing the same substance. NADP+ follows the same naming logic with phosphate added. Knowing the nomenclature helps when ordering reference material, because catalogues list free acid, disodium salt and hydrate forms with different molecular weights, and a certificate of analysis should state which one the lyophilised vial contains along with HPLC purity and mass confirmation. Investigators new to cofactor terminology often arrive from peptide research basics, from longevity compound overviews, or from reading on current regulatory expectations.

Where does NAD+ come from in cells (de novo, Preiss-Handler and salvage pathways)?

Cells build NAD+ by three converging routes. The de novo pathway starts from the amino acid tryptophan and runs through the kynurenine series to quinolinic acid, which quinolinate phosphoribosyltransferase converts to nicotinic acid mononucleotide. The Preiss-Handler pathway starts from nicotinic acid, uses nicotinate phosphoribosyltransferase to make the same intermediate, and then proceeds through NMN adenylyltransferases and NAD synthetase. The salvage pathway, generally considered the dominant contributor in most mammalian tissues, recycles nicotinamide released by NAD-consuming enzymes. Nicotinamide phosphoribosyltransferase, abbreviated NAMPT, converts it to nicotinamide mononucleotide, and NMNAT enzymes then adenylylate that to NAD+. Nicotinamide riboside enters through nicotinamide riboside kinases, bypassing NAMPT.

Because salvage dominates, the rate-limiting step in many tissues is NAMPT activity rather than raw precursor availability, which is why preclinical work frequently manipulates NAMPT expression or uses inhibitors such as FK866 as negative controls. Compartmentalisation matters too, since mitochondrial, nuclear and cytosolic pools are maintained by different NMNAT isoforms. These pathway questions sit alongside the wider literature on metabolic research compounds and longevity research peptides, and sourcing clean pathway intermediates depends on the verification steps described in supplier vetting.

What are NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide, nicotinic acid, nicotinamide) as research compounds?

Four precursors appear most often in benchwork. Nicotinamide, the simplest, is released by NAD-consuming enzymes and re-enters through NAMPT, but it also inhibits sirtuins at higher concentrations, which complicates interpretation. Nicotinic acid feeds the Preiss-Handler route and additionally binds the GPR109A receptor, a pharmacology unrelated to NAD+ itself that can confound results. Nicotinamide riboside, characterised as a distinct precursor in the 2000s, enters via nicotinamide riboside kinases. Nicotinamide mononucleotide sits one step closer to NAD+ and is generally reported to require dephosphorylation or specific transport before cellular uptake.

As purchased materials, all four are small molecules rather than peptides, usually supplied as lyophilised powders or crystalline solids. Certificates of analysis should report HPLC purity, mass spectrometric identity, residual solvents and water content, since nicotinamide riboside chloride in particular is hygroscopic and degrades in humid or warm conditions. Cold, dry, light-protected storage of sealed vials is standard. In most jurisdictions these are sold strictly for laboratory research and are not for human consumption, a boundary explained further in the overview of legal status and FDA expectations. Buyers comparing them with other research compounds or with 5-amino-1MQ should apply the same supplier checks.

What is the NAD+/NADH ratio and how is it measured in the laboratory?

The NAD+/NADH ratio expresses how oxidised a given compartment is. Free cytosolic ratios are generally reported as far higher than mitochondrial ratios, which supports glycolytic flux in the cytosol and electron delivery in mitochondria. The ratio, not absolute concentration alone, governs the direction of dehydrogenase reactions, so it is often the more informative readout in metabolic experiments.

Measurement approaches fall into several families. Enzymatic cycling assays use alcohol dehydrogenase or diaphorase chemistry with selective acid or alkaline extraction to destroy one species and quantify the other. Direct chromatographic methods, typically LC-MS/MS or ion-pair HPLC with ultraviolet detection, separate NAD+, NADH, NADP+ and NADPH in a single run and give absolute concentrations when calibrated against certified standards. Genetically encoded fluorescent biosensors such as the Peredox and SoNar families report free cytosolic ratios in living cells without extraction. Indirect estimation from the lactate to pyruvate ratio remains common because it reflects free rather than protein-bound cofactor.

Whichever method is chosen, results depend on standards of verified purity, which is why HPLC and mass data on the certificate matter, and why supplier verification is relevant to anyone working with research-grade materials in metabolic studies.

Which enzymes consume NAD+ (sirtuins, PARPs, CD38)?

Unlike dehydrogenases, which recycle the cofactor, three enzyme families cleave NAD+ and destroy it, releasing nicotinamide as a by-product. Sirtuins, the seven mammalian SIRT isoforms, are NAD-dependent deacylases that remove acetyl and other acyl groups from lysine residues on histones and metabolic enzymes, producing 2'-O-acyl-ADP-ribose. Their activity is therefore tied directly to cofactor availability, which is the mechanistic basis for most sirtuin-centred ageing hypotheses. PARPs, led by PARP1, attach poly-ADP-ribose chains to proteins during DNA damage responses and can consume large amounts of NAD+ when damage is extensive. CD38 and the related CD157 are glycohydrolases that degrade NAD+ and NMN and generate calcium-mobilising messengers such as cyclic ADP-ribose; CD38 expression is frequently described as rising with age in preclinical tissue studies.

Because nicotinamide is the shared product, these enzymes feed back into the salvage pathway and also inhibit sirtuins at accumulated concentrations. Experimentally, selective inhibitors and knockout models are used to separate the contributions of each family. This enzymology underpins much of the interest in longevity research compounds, overlaps with cognitive and nootropic research through neuronal axon degeneration pathways, and connects to methylation-focused materials such as 5-amino-1MQ.

Is NAD+ the same as niacin or vitamin B3?

No. Vitamin B3 is an umbrella term for a group of related pyridine compounds, principally nicotinic acid, which is niacin in the strict sense, and nicotinamide, also called niacinamide. These are precursors. NAD+ is the much larger dinucleotide that cells assemble from them, containing a nicotinamide ring, an adenine ring, two riboses and a pyrophosphate bridge. Saying NAD+ is vitamin B3 is roughly like saying a brick is a building.

The distinction has practical consequences. Nicotinic acid and nicotinamide have different pharmacology despite both feeding NAD+ synthesis, with nicotinic acid acting at GPR109A and nicotinamide inhibiting sirtuins at sufficient concentration. Newer precursors such as nicotinamide riboside and nicotinamide mononucleotide are sometimes marketed as forms of vitamin B3, but they enter the network through different enzymes. For laboratory procurement, identity confirmation by mass spectrometry is essential because molecular weights differ substantially across these compounds, and HPLC purity figures should appear on every certificate of analysis. All of these materials are supplied for research use only and are not for human consumption, a point detailed in the discussion of regulatory status. The same identity and documentation standards described for research compounds generally and in supplier assessment apply here.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

1. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
2. NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
3. Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
4. NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
5. NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
6. Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
7. FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
8. NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443